- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...
CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
Clasp’s model helps healthcare employers commit to clinicians before graduation and ties student loan repayment to employee tenure, replacing transactional sign-on bonuses with retention-based ...
The health care industry was already facing a looming worker shortage from retirements and increasing demand when Republicans in Washington made things worse last week. The massive tax and spending ...
Clasp Therapeutics, a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company connects healthcare ...
The microtubule cytoskeleton is, to a large extent, responsible for the dynamic architecture of the cytoplasm, including global changes associated with cell cycle progression. To adapt to dynamic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results